Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Barr PM"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-19 z 19
    Tytuł:
    Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium.
    Autorzy:
    Vose JM; Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Nebraska Medicine Fred and Pamela Buffett Cancer Center, 505 S 45Th St, Omaha, NE, 68105, USA.
    Fu K; Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
    Wang L; School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai, China.
    Mansoor A; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada.
    Stewart D; Departments of Oncology and Medicine, University of Calgary, Calgary, Canada.
    Cheng H; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.; Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
    Smith L; Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE, USA.
    Yuan J; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
    Qureishi HN; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
    Link BK; Department of Internal Medicine, University of Iowa Hospitals & Clinics, Iowa City, Iowa, USA.
    Cessna MH; Department of Pathology, Intermountain Medical Center, Murray, UT, USA.
    Barr PM; Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
    Kahl BS; Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
    Mckinney MS; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA.
    Khan N; Department of Hematology/Oncology, Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
    Advani RH; Division of Oncology, Stanford Cancer Institute, Stanford, CA, USA.
    Martin P; Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY, USA.
    Goy AH; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.
    Phillips TJ; Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI, USA.
    Mehta A; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
    Kamdar M; Division of Hematology, University of Colorado, Denver, CO, USA.
    Crump M; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre - University Health Network, Toronto, ON, Canada.
    Pro B; Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, USA.
    Flowers CR; Division of Cancer Medicine, Department of Lymphoma-Myeloma, MD Anderson Cancer Center, Houston, TX, USA.
    Jacobson CA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
    Smith SM; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA.
    Stephens DM; Huntsman Cancer Institute at University of Utah, Salt Lake City, UT, USA.
    Bachanova V; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
    Jin Z; Department of Oncology, Mayo Clinic, Rochester, MN, USA.
    Wu S; Department of Pathology, Affiliated Yantai Yuhuangding Hospital, Qingdao University, No.20 Yuhuangding East Road, Yantai, 264000, China.
    Hernandez-Ilizaliturri F; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
    Torka P; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Anampa-Guzmán A; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
    Kashef F; Department of Pathology, University at Buffalo, Buffalo, NY, USA.
    Li X; Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
    Sharma S; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
    Greiner TC; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
    Armitage JO; Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Nebraska Medicine Fred and Pamela Buffett Cancer Center, 505 S 45Th St, Omaha, NE, 68105, USA.
    Lunning M; Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Nebraska Medicine Fred and Pamela Buffett Cancer Center, 505 S 45Th St, Omaha, NE, 68105, USA.
    Weisenburger DD; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
    Bociek RG; Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Nebraska Medicine Fred and Pamela Buffett Cancer Center, 505 S 45Th St, Omaha, NE, 68105, USA.
    Iqbal J; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
    Yu G; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA. .; Department of Pathology, Affiliated Yantai Yuhuangding Hospital, Qingdao University, No.20 Yuhuangding East Road, Yantai, 264000, China. .
    Bi C; Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Nebraska Medicine Fred and Pamela Buffett Cancer Center, 505 S 45Th St, Omaha, NE, 68105, USA. .
    Pokaż więcej
    Corporate Authors:
    North American Mantle Cell Lymphoma Consortium
    Źródło:
    Journal of hematology & oncology [J Hematol Oncol] 2023 Dec 16; Vol. 16 (1), pp. 122. Date of Electronic Publication: 2023 Dec 16.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Lymphoma, Mantle-Cell*/drug therapy
    Lymphoma, Mantle-Cell*/pathology
    Adult ; Humans ; Prognosis ; Retrospective Studies ; Risk Factors ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; North America
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study.
    Autorzy:
    Woyach JA; Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
    Barr PM; Wilmot Cancer Institute, University of Rochester, Rochester, NY 14642, USA.
    Kipps TJ; University of California San Diego Moores Cancer Center, San Diego, CA 92037, USA.
    Barrientos JC; Mount Sinai Comprehensive Cancer Center, Miami Beach, FL 33140, USA.
    Ahn IE; Laboratory of Lymphoid Malignancies, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20814, USA.
    Ghia P; Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, 20132 Milan, Italy.
    Girardi V; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA 94080, USA.
    Hsu E; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA 94080, USA.
    Jermain M; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA 94080, USA.
    Burger JA; University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2023 Jan 13; Vol. 15 (2). Date of Electronic Publication: 2023 Jan 13.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
    Autorzy:
    Siddiqi T; City of Hope National Medical Center, Duarte, CA, USA.
    Coutre S; Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA, USA.
    McKinney M; Duke University, Durham, NC, USA.
    Barr PM; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
    Rogers K; Ohio State University, Columbus, OH, USA.
    Mokatrin A; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA.
    Valentino R; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA.
    Szoke A; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA.
    Deshpande S; Johnson & Johnson, Raritan, NJ, USA.
    Zhu A; Johnson & Johnson, Raritan, NJ, USA.
    Arango-Hisijara I; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA.
    Osei-Bonsu K; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA.
    Wang M; The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
    O'Brien S; UC Irvine, Chao Family Comprehensive Cancer Center, Irvine, CA, USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2022 Jul; Vol. 63 (7), pp. 1580-1588. Date of Electronic Publication: 2022 Feb 28.
    Typ publikacji:
    Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Leukemia, Lymphocytic, Chronic, B-Cell*/complications
    Leukemia, Lymphocytic, Chronic, B-Cell*/diagnosis
    Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
    Lymphoma, Mantle-Cell*/drug therapy
    Lymphoma, Mantle-Cell*/pathology
    Musculoskeletal Pain*/chemically induced
    Musculoskeletal Pain*/diagnosis
    Adenine/analogs & derivatives ; Adult ; Arthralgia/chemically induced ; Arthralgia/drug therapy ; Humans ; Myalgia/chemically induced ; Myalgia/diagnosis ; Piperidines ; Protein Kinase Inhibitors/adverse effects ; Pyrazoles/adverse effects ; Pyrimidines/adverse effects
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.
    Autorzy:
    Barr PM; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
    Smith SD; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
    Roschewski MJ; National Cancer Institute, Bethesda, MD, USA.
    O'Brien SM; Chao Family Comprehensive Cancer Center, University of California-Irvine, Irvine, CA, USA.
    Sharman JP; Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR, USA.
    Melear JM; Texas Oncology, Austin, TX, USA.
    Patel P; AstraZeneca, South San Francisco, CA, USA.
    Calvo R; AstraZeneca, Gaithersburg, MD, USA.
    Yang H; AstraZeneca, South San Francisco, CA, USA.
    Spurgeon SE; Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR, USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2022 Jul; Vol. 63 (7), pp. 1728-1732. Date of Electronic Publication: 2022 Feb 24.
    Typ publikacji:
    Clinical Trial, Phase I; Clinical Trial, Phase II; Letter; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Lymphoma, B-Cell*/drug therapy
    Lymphoma, B-Cell*/pathology
    Phosphatidylinositol 3-Kinases*
    Adenosine ; Benzamides ; Humans ; Pyrazines ; Quinolines
    Raport
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Autorzy:
    Woyach J; Division of Hematology, Department of Internal Medicine, The Ohio State University Medical Center, Columbus, OH, USA.
    Tedeschi A; Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
    Munir T; Department of Haematology, St. James's University Hospital, Leeds, UK.
    Siddiqi T; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.
    Hillmen P; Department of Haematology, The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, UK.
    Byrd JC; Division of Hematology, Department of Internal Medicine, The Ohio State University Medical Center, Columbus, OH, USA.
    Ghia P; Division of Experimental Oncology, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy.
    Mulligan SP; Department of Haematology, Royal North Shore Hospital, University of Sydney, Sydney, Australia.
    Dai S; Department of Biostatistics, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
    Amaya-Chanaga CI; Department of Medical Affairs, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
    Dean JP; Department of Clinical Science, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
    O'Brien SM; Department of Hematology and Oncology, UC Irvine, Chao Family Comprehensive Cancer Center, Irvine, CA, USA.
    Barr PM; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2021 Dec; Vol. 62 (13), pp. 3278-3282. Date of Electronic Publication: 2021 Aug 13.
    Typ publikacji:
    Letter; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Leukemia, Lymphocytic, Chronic, B-Cell*/diagnosis
    Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
    Leukemia, Lymphocytic, Chronic, B-Cell*/pathology
    Adenine/analogs & derivatives ; Humans ; Piperidines ; Protein Kinase Inhibitors/adverse effects
    Raport
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma.
    Autorzy:
    Rodgers TD; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
    Williams AM; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
    Baran A; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
    Reagan PM; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
    Casulo C; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
    Zent CS; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
    Evans A; Department of Pathology, University of Rochester Medical Center, Rochester, NY, USA.
    Friedberg JW; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
    Barr PM; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2021 Mar; Vol. 62 (3), pp. 598-605. Date of Electronic Publication: 2020 Oct 25.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Antineoplastic Agents*/therapeutic use
    Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
    Lymphoma, Non-Hodgkin*/drug therapy
    Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Humans ; Phosphatidylinositol 3-Kinase ; Phosphatidylinositol 3-Kinases/genetics ; Retrospective Studies
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
    Autorzy:
    Cuneo A; Hematology, Department of Medical Sciences, St. Anna University Hospital, Ferrara, Italy.
    Mato AR; Division of Hematological Oncology, CLL Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Rigolin GM; Hematology, Department of Medical Sciences, St. Anna University Hospital, Ferrara, Italy.
    Piciocchi A; Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
    Gentile M; Department of Onco-Hematology, Hematology Unit, A.O. of Cosenza, Cosenza, Italy.
    Laurenti L; Department of Radiological, Radiotherapeutic and Hematological Sciences, Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, Rome, Italy.
    Allan JN; Weill Cornell Medicine, New York, NY, USA.
    Pagel JM; Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA.
    Brander DM; Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA.
    Hill BT; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
    Winter A; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
    Lamanna N; Columbia University Medical Center, New York, NY, USA.
    Tam CS; Peter McCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
    Jacobs R; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, USA.
    Lansigan F; Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
    Barr PM; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
    Shadman M; Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA.
    Skarbnik AP; Lymphoproliferative Disorders Program, Novant Health Cancer Institute, Charlotte, NC, USA.
    Pu JJ; SUNY Upstate Medical University, SUNY Upstate Medical University, Syracuse, NY, USA.
    Sehgal AR; University of Pittsburgh, Pittsburgh, PA, USA.
    Schuster SJ; Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.
    Shah NN; Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
    Ujjani CS; Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA.
    Roeker L; Division of Hematological Oncology, CLL Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Orlandi EM; Hematology Unit, IRCCS Policlinico San Matteo, Pavia, Italy.
    Billio A; Hematology and Transplant Unit, San Maurizio Hospital, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy.
    Trentin L; Hematology and Clinical Immunology, Department of Medicine, University of Padua, Padua, Italy.
    Spacek M; Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
    Marchetti M; Oncology Unit, Cardinal Massaia Hospital, Asti, Italy.
    Tedeschi A; Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
    Ilariucci F; Hematology, Azienda USL-IRCCS, Reggio Emilia, Italy.
    Gaidano G; Division of Hematology, Department of Translational Medicine, University of eastern Piedmont, Novara, Italy.
    Doubek M; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
    Farina L; Hematology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.
    Molica S; Hematology Unit, A. Pugliese Hospital, Azienda Ospedaliera Pugliese Ciaccio, Catanzaro, Italy.
    Di Raimondo F; Catania Università di Catania, Cattedra di Ematologia, Catania, Italy.
    Coscia M; Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
    Mauro FR; Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome, Italy.
    de la Serna J; Hematology Unit, Hospital Universitario, Madrid, Spain.
    Medina Perez A; Hospital Costa del Sol, Marbella, Spain.
    Ferrarini I; Hematology, Department of Cell Therapy and Hematology, University Hospital, Verona, Italy.
    Cimino G; Department of Translational and Precision Medicine, University 'La Sapienza', UOC di Ematologia con Trapianto, Ospedale S. Maria Goretti, Latina, Italy.
    Cavallari M; Hematology, Department of Medical Sciences, St. Anna University Hospital, Ferrara, Italy.
    Cucci R; Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
    Vignetti M; Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
    Foà R; Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome, Italy.
    Ghia P; Strategic Research Program on CLL, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele, Milan, Italy.
    Pokaż więcej
    Corporate Authors:
    GIMEMA, European Research Initiative (ERIC) on CLL, US study group
    Źródło:
    Cancer medicine [Cancer Med] 2020 Nov; Vol. 9 (22), pp. 8468-8479. Date of Electronic Publication: 2020 Sep 24.
    Typ publikacji:
    Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Adenine/*analogs & derivatives
    Antineoplastic Agents, Alkylating/*therapeutic use
    Antineoplastic Agents, Immunological/*therapeutic use
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Bendamustine Hydrochloride/*therapeutic use
    Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
    Piperidines/*therapeutic use
    Protein Kinase Inhibitors/*therapeutic use
    Rituximab/*therapeutic use
    Adenine/adverse effects ; Adenine/therapeutic use ; Aged ; Antineoplastic Agents, Alkylating/adverse effects ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bendamustine Hydrochloride/adverse effects ; Disease Progression ; Europe ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell/mortality ; Male ; Middle Aged ; Piperidines/adverse effects ; Progression-Free Survival ; Protein Kinase Inhibitors/adverse effects ; Retrospective Studies ; Rituximab/adverse effects ; Time Factors ; United States
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Cognitive function in patients with chronic lymphocytic leukemia: a cross-sectional study examining effects of disease and treatment.
    Autorzy:
    Williams AM; Department of Public Health Sciences, University of Rochester Medical Center, Rochester, NY, USA.; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
    van Wijngaarden E; Department of Public Health Sciences, University of Rochester Medical Center, Rochester, NY, USA.
    Seplaki CL; Department of Public Health Sciences, University of Rochester Medical Center, Rochester, NY, USA.
    Heckler CE; Department of Surgery, University of Rochester Medical Center, Rochester, NY, USA.
    Weber MT; Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA.
    Barr PM; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.; Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
    Zent CS; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.; Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
    Janelsins MC; James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.; Department of Surgery, University of Rochester Medical Center, Rochester, NY, USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2020 Jul; Vol. 61 (7), pp. 1627-1635. Date of Electronic Publication: 2020 Mar 09.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Cognitive Dysfunction*/diagnosis
    Cognitive Dysfunction*/epidemiology
    Cognitive Dysfunction*/etiology
    Leukemia, Lymphocytic, Chronic, B-Cell*/complications
    Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
    Leukemia, Myeloid, Acute*
    Cognition ; Cross-Sectional Studies ; Humans
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL).
    Autorzy:
    Meacham PJ; Wilmot Cancer Institute, Rochester, NY, USA.
    Williams AM; Wilmot Cancer Institute, Rochester, NY, USA.
    Strawderman M; Wilmot Cancer Institute, Rochester, NY, USA.
    Baran AM; Wilmot Cancer Institute, Rochester, NY, USA.
    Archibald WJ; School of Medicine and Dentistry, Rochester, NY, USA.
    Wallace DS; School of Medicine and Dentistry, Rochester, NY, USA.
    Tschernia NP; School of Medicine and Dentistry, Rochester, NY, USA.
    Burack WR; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.
    Barr PM; Wilmot Cancer Institute, Rochester, NY, USA.
    Zent CS; Wilmot Cancer Institute, Rochester, NY, USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2020 Jul; Vol. 61 (7), pp. 1636-1644. Date of Electronic Publication: 2020 Mar 16.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Leukemia, Lymphocytic, Chronic, B-Cell*/diagnosis
    Leukemia, Lymphocytic, Chronic, B-Cell*/epidemiology
    Lymphoma, B-Cell*
    B-Lymphocytes ; Humans ; Incidence ; Risk Factors
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation.
    Autorzy:
    Loh KP; James P. Wilmot Cancer Center, Division of Hematology and Oncology, University of Rochester Medical Center, Rochester, NY, USA.
    Baran A; James P. Wilmot Cancer Center, Division of Hematology and Oncology, University of Rochester Medical Center, Rochester, NY, USA.
    Lee CY; Meyer Cancer Center, Weill Cornell Medicine and New York-Presbyterian Hospital, Department of Medicine, New York, NY, USA.
    Alshaibani A; Meyer Cancer Center, Weill Cornell Medicine and New York-Presbyterian Hospital, Department of Medicine, New York, NY, USA.
    Rutherford SC; Meyer Cancer Center, Weill Cornell Medicine and New York-Presbyterian Hospital, Department of Medicine, New York, NY, USA.
    Hu J; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
    Casulo C; James P. Wilmot Cancer Center, Division of Hematology and Oncology, University of Rochester Medical Center, Rochester, NY, USA.
    Barr PM; James P. Wilmot Cancer Center, Division of Hematology and Oncology, University of Rochester Medical Center, Rochester, NY, USA.
    Friedberg JW; James P. Wilmot Cancer Center, Division of Hematology and Oncology, University of Rochester Medical Center, Rochester, NY, USA.
    Reagan PM; James P. Wilmot Cancer Center, Division of Hematology and Oncology, University of Rochester Medical Center, Rochester, NY, USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2019 Dec; Vol. 60 (14), pp. 3569-3572. Date of Electronic Publication: 2019 Jul 08.
    Typ publikacji:
    Letter
    MeSH Terms:
    Patient Selection*
    Clinical Trials as Topic/*standards
    Lymphoma, Large B-Cell, Diffuse/*pathology
    Lymphoma, Large B-Cell, Diffuse/*therapy
    Research Design/*standards
    Aged ; Disease Progression ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Prognosis ; Retrospective Studies
    Opinia redakcyjna
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies.
    Autorzy:
    Williams AM; a Wilmot Cancer Institute, University of Rochester , Rochester , NY , USA.
    Baran AM; a Wilmot Cancer Institute, University of Rochester , Rochester , NY , USA.
    Meacham PJ; a Wilmot Cancer Institute, University of Rochester , Rochester , NY , USA.
    Feldman MM; a Wilmot Cancer Institute, University of Rochester , Rochester , NY , USA.
    Valencia HE; b Department of Internal Medicine , University of Rochester , Rochester , NY , USA.
    Newsom-Stewart C; a Wilmot Cancer Institute, University of Rochester , Rochester , NY , USA.
    Gupta N; a Wilmot Cancer Institute, University of Rochester , Rochester , NY , USA.
    Janelsins MC; a Wilmot Cancer Institute, University of Rochester , Rochester , NY , USA.; c Department of Surgery , University of Rochester , Rochester , NY , USA.
    Barr PM; a Wilmot Cancer Institute, University of Rochester , Rochester , NY , USA.
    Zent CS; a Wilmot Cancer Institute, University of Rochester , Rochester , NY , USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2018 Mar; Vol. 59 (3), pp. 625-632. Date of Electronic Publication: 2017 Jul 11.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Communicable Diseases/*diagnosis
    Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
    Molecular Targeted Therapy/*adverse effects
    Pyrazoles/*adverse effects
    Pyrimidines/*adverse effects
    Adenine/analogs & derivatives ; Communicable Diseases/chemically induced ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Piperidines ; Prognosis ; Risk Factors
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective.
    Autorzy:
    Reid RM; James P Wilmot Cancer Institute and Department of Medicine, University of Rochester Medical Center, Rochester, New York.; Rochester Regional Health, Rochester, New York.
    Baran A; James P Wilmot Cancer Institute and Department of Medicine, University of Rochester Medical Center, Rochester, New York.
    Friedberg JW; James P Wilmot Cancer Institute and Department of Medicine, University of Rochester Medical Center, Rochester, New York.
    Phillips GL 2nd; James P Wilmot Cancer Institute and Department of Medicine, University of Rochester Medical Center, Rochester, New York.; Wake Forest Baptist Health, Winston-Salem, North Carolina.
    Liesveld JL; James P Wilmot Cancer Institute and Department of Medicine, University of Rochester Medical Center, Rochester, New York.
    Becker MW; James P Wilmot Cancer Institute and Department of Medicine, University of Rochester Medical Center, Rochester, New York.
    Wedow L; James P Wilmot Cancer Institute and Department of Medicine, University of Rochester Medical Center, Rochester, New York.
    Barr PM; James P Wilmot Cancer Institute and Department of Medicine, University of Rochester Medical Center, Rochester, New York.
    Milner LA; James P Wilmot Cancer Institute and Department of Medicine, University of Rochester Medical Center, Rochester, New York.; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York.
    Pokaż więcej
    Źródło:
    Cancer medicine [Cancer Med] 2016 Nov; Vol. 5 (11), pp. 3059-3067. Date of Electronic Publication: 2016 Oct 03.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Hematopoietic Stem Cell Transplantation*/adverse effects
    Hematopoietic Stem Cell Transplantation*/methods
    Transplantation Conditioning*/adverse effects
    Transplantation Conditioning*/methods
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Lymphoma/*therapy
    Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carmustine/adverse effects ; Carmustine/therapeutic use ; Combined Modality Therapy ; Cost-Benefit Analysis ; Cytarabine/adverse effects ; Cytarabine/therapeutic use ; Female ; Follow-Up Studies ; Health Care Costs ; Humans ; Infections/etiology ; Kaplan-Meier Estimate ; Lymphoma/diagnosis ; Lymphoma/mortality ; Male ; Melphalan/adverse effects ; Melphalan/therapeutic use ; Middle Aged ; Outpatients ; Podophyllotoxin/adverse effects ; Podophyllotoxin/therapeutic use ; Transplantation, Autologous ; Young Adult
    SCR Protocol:
    BEAM protocol
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.
    Autorzy:
    Holkova B; a Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .; b Department of Internal Medicine , Virginia Commonwealth University , Richmond , VA , USA .
    Kmieciak M; a Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .
    Bose P; c University of Texas MD Anderson Cancer Center , Houston , TX , USA .
    Yazbeck VY; a Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .; b Department of Internal Medicine , Virginia Commonwealth University , Richmond , VA , USA .
    Barr PM; d James P. Wilmot Cancer Center, University of Rochester , Rochester , NY , USA .
    Tombes MB; a Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .
    Shrader E; a Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .
    Weir-Wiggins C; a Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .
    Rollins AD; a Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .
    Cebula EM; d James P. Wilmot Cancer Center, University of Rochester , Rochester , NY , USA .
    Pierce E; d James P. Wilmot Cancer Center, University of Rochester , Rochester , NY , USA .
    Herr M; d James P. Wilmot Cancer Center, University of Rochester , Rochester , NY , USA .
    Sankala H; a Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .
    Hogan KT; a Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .
    Wan W; e Department of Biostatistics , Virginia Commonwealth University , Richmond , VA , USA .
    Feng C; d James P. Wilmot Cancer Center, University of Rochester , Rochester , NY , USA .; f Department of Biostatistics and Computational Biology , University of Rochester , Rochester , NY , USA .
    Peterson DR; f Department of Biostatistics and Computational Biology , University of Rochester , Rochester , NY , USA .
    Fisher RI; g Fox Chase Cancer Center , Temple Health , Philadelphia , PA , USA .
    Grant S; a Massey Cancer Center and Virginia Commonwealth University , Richmond , VA , USA .; b Department of Internal Medicine , Virginia Commonwealth University , Richmond , VA , USA .; h Department of Microbiology and Immunology , Virginia Commonwealth University , Richmond , VA , USA .; i Department of Biochemistry and Molecular Biology , Virginia Commonwealth University , Richmond , VA , USA .; j The Institute for Molecular Medicine , Virginia Commonwealth University , Richmond , VA , USA , and.
    Friedberg JW; d James P. Wilmot Cancer Center, University of Rochester , Rochester , NY , USA .; k Department of Medicine , University of Rochester , Rochester, NY , USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2016; Vol. 57 (3), pp. 635-43. Date of Electronic Publication: 2015 Oct 12.
    Typ publikacji:
    Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Lymphoma, B-Cell/*diagnosis
    Lymphoma, B-Cell/*drug therapy
    Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Biomarkers ; Combined Modality Therapy ; Cytokines/blood ; Drug Monitoring ; Drug Resistance, Neoplasm ; Female ; Humans ; Hydroxamic Acids/administration & dosage ; Lymphoma, B-Cell/blood ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Oligopeptides/administration & dosage ; Retreatment ; Treatment Outcome ; Vorinostat
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
    Autorzy:
    Wilson WH; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA.
    Young RM; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA.
    Schmitz R; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA.
    Yang Y; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA.
    Pittaluga S; Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, Maryland, USA.
    Wright G; Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland, USA.
    Lih CJ; Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
    Williams PM; Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
    Shaffer AL; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA.
    Gerecitano J; 1] Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. [2] Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
    de Vos S; Division of Hematology and Oncology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, USA.
    Goy A; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
    Kenkre VP; Division of Hematology and Medical Oncology, University of Wisconsin, Madison, Wisconsin, USA.
    Barr PM; James P. Wilmot Cancer Center, University of Rochester, Rochester, New York, USA.
    Blum KA; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
    Shustov A; Department of Medicine, Hematology, University of Washington School of Medicine, Seattle, Washington, USA.
    Advani R; Medical Oncology, Stanford University Medical Center, Stanford, California, USA.
    Fowler NH; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
    Vose JM; Division of Hematology &Oncology, Department of Internal Medicine, University of Nebraska, Omaha, Nebraska, USA.
    Elstrom RL; Clinical Development, Genentech, Inc., South San Francisco, California, USA.
    Habermann TM; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
    Barrientos JC; Division of Hematology and Medical Oncology, Department of Medicine, Hofstra North Shore-Long Island Jewish School of Medicine, Hempstead, New York, USA.
    McGreivy J; Pharmacyclics, Inc., Sunnyvale, California, USA.
    Fardis M; Pharmacyclics, Inc., Sunnyvale, California, USA.
    Chang BY; Pharmacyclics, Inc., Sunnyvale, California, USA.
    Clow F; Pharmacyclics, Inc., Sunnyvale, California, USA.
    Munneke B; Pharmacyclics, Inc., Sunnyvale, California, USA.
    Moussa D; Pharmacyclics, Inc., Sunnyvale, California, USA.
    Beaupre DM; Pharmacyclics, Inc., Sunnyvale, California, USA.
    Staudt LM; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA.
    Pokaż więcej
    Źródło:
    Nature medicine [Nat Med] 2015 Aug; Vol. 21 (8), pp. 922-6. Date of Electronic Publication: 2015 Jul 20.
    Typ publikacji:
    Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Lymphoma, Large B-Cell, Diffuse/*drug therapy
    Protein Kinase Inhibitors/*pharmacology
    Pyrazoles/*pharmacology
    Pyrimidines/*pharmacology
    Receptors, Antigen, B-Cell/*physiology
    Signal Transduction/*drug effects
    Adenine/analogs & derivatives ; Adult ; Aged ; Base Sequence ; CD79 Antigens/genetics ; Female ; Humans ; Lymphoma, Large B-Cell, Diffuse/genetics ; Lymphoma, Large B-Cell, Diffuse/mortality ; Male ; Middle Aged ; Molecular Sequence Data ; Mutation ; Myeloid Differentiation Factor 88/genetics ; Piperidines
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Infection in chronic lymphocytic leukemia: parsimony has its limits.
    Autorzy:
    Barr PM; Division of Hematology/Oncology, James P. Wilmot Cancer Center, University of Rochester , Rochester, NY , USA.
    Zent CS
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2014 Dec; Vol. 55 (12), pp. 2683-4. Date of Electronic Publication: 2014 May 16.
    Typ publikacji:
    Journal Article; Comment
    MeSH Terms:
    Virus Activation*
    Epstein-Barr Virus Infections/*complications
    Herpesvirus 4, Human/*physiology
    Leukemia, Lymphocytic, Chronic, B-Cell/*complications
    Lymphohistiocytosis, Hemophagocytic/*etiology
    Humans
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    The ABC of chronic lymphocytic leukemia: etiology of cytopenias is important in staging and management.
    Autorzy:
    Barr PM; James P. Wilmot Cancer Center, University of Rochester , Rochester, NY , USA.
    Zent CS
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2014 Jun; Vol. 55 (6), pp. 1219-20. Date of Electronic Publication: 2013 Nov 01.
    Typ publikacji:
    Journal Article; Comment
    MeSH Terms:
    Autoimmune Diseases/*etiology
    Leukemia, Lymphocytic, Chronic, B-Cell/*complications
    Leukemia, Lymphocytic, Chronic, B-Cell/*pathology
    Pancytopenia/*etiology
    Female ; Humans ; Male
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia.
    Autorzy:
    Herman SE
    Barr PM
    McAuley EM
    Liu D
    Wiestner A
    Friedberg JW
    Pokaż więcej
    Źródło:
    Leukemia [Leukemia] 2013 Aug; Vol. 27 (8), pp. 1769-73. Date of Electronic Publication: 2013 Feb 06.
    Typ publikacji:
    Letter; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Agents/*pharmacology
    Leukemia, Lymphocytic, Chronic, B-Cell/*metabolism
    Oxazines/*pharmacology
    Protein Kinase Inhibitors/*pharmacology
    Pyridines/*pharmacology
    Receptors, Antigen, B-Cell/*antagonists & inhibitors
    Signal Transduction/*drug effects
    Aminopyridines ; Antineoplastic Agents/therapeutic use ; Cell Proliferation/drug effects ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Morpholines ; Oxazines/therapeutic use ; Protein Kinase Inhibitors/therapeutic use ; Pyridines/therapeutic use ; Pyrimidines ; Receptors, Antigen, B-Cell/metabolism
    Raport
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Getting to the heart of the problem in treating diffuse large B-cell lymphoma.
    Autorzy:
    Barr PM; James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA.
    Friedberg JW
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2011 Jul; Vol. 52 (7), pp. 1166-7. Date of Electronic Publication: 2011 May 25.
    Typ publikacji:
    Journal Article; Comment
    MeSH Terms:
    Antibiotics, Antineoplastic/*therapeutic use
    Doxorubicin/*therapeutic use
    Lymphoma, Large B-Cell, Diffuse/*drug therapy
    Female ; Humans ; Male
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia.
    Autorzy:
    Harr MW; Department of Medicine, Case Western Reserve University, Cleveland, Ohio 44106-7285, USA.
    Caimi PF
    McColl KS
    Zhong F
    Patel SN
    Barr PM
    Distelhorst CW
    Pokaż więcej
    Źródło:
    Cell death and differentiation [Cell Death Differ] 2010 Sep; Vol. 17 (9), pp. 1381-91. Date of Electronic Publication: 2010 Mar 19.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural
    MeSH Terms:
    Apoptosis/*drug effects
    Drug Resistance, Neoplasm/*drug effects
    Glucocorticoids/*pharmacology
    Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
    Leukemia, Lymphocytic, Chronic, B-Cell/*pathology
    Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/*antagonists & inhibitors
    Lymphocytes/*cytology
    Lymphocytes/*drug effects
    Animals ; Apoptosis/immunology ; B-Lymphocytes/metabolism ; Calcium Signaling/drug effects ; Calcium Signaling/immunology ; Cell Line, Tumor ; Cells, Cultured ; Dasatinib ; Dexamethasone/pharmacology ; Down-Regulation/genetics ; Drug Synergism ; Gene Expression Profiling ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/metabolism ; Leukocytes, Mononuclear/cytology ; Leukocytes, Mononuclear/drug effects ; Leukocytes, Mononuclear/metabolism ; Lymphocyte Activation/drug effects ; Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/genetics ; Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/metabolism ; Lymphocytes/immunology ; Mice ; Mice, Inbred Strains ; Phosphorylation/drug effects ; Protein Kinase Inhibitors/pharmacology ; Pyrimidines/pharmacology ; RNA, Small Interfering/genetics ; Receptors, Antigen, T-Cell/agonists ; Signal Transduction/drug effects ; Signal Transduction/immunology ; T-Lymphocytes/drug effects ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; Thiazoles/pharmacology ; Tumor Cells, Cultured
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-19 z 19

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies